Dr. Tho Lye codd oncology

Dr. Tho Lye codd est in summo oncologist in Kuala Lumpur elit.

D. Tho Lye codd perficitur et postgraduate adipiscing orci sub disciplina in Australia et Canada doctrina progressio. Ipse est qualified in Latin and Greek (MRCP) Pharmacopoeia Collegii Regalis in Fellowship tenet et in UK radiologists C. Scandinavica (FRCR) itemque plenam UK specialist accreditation. Tum persequi erat occupata a CLINICUS physicus vitae in solutae orationis hypothetica oncology in prestigious CRUK / DNA ad quae se consideratum sit amet variis propositis praemiis et inter quas Iohannes Paulus Award Annam Hollman Medal. Et servivit in qua socius Aggregatus Professor Malaya Universitatis prius in privata usu movere.

In statu Dr Tho est Vice Praeses SEAROG (South East Asia Radiatio Oncologiae Group) et agit in technicis radiorum provectis explicandis eg. SRS, SBRT/SABR. Est etiam Vice Praeses LCNM (Lung Cancer Network Malaysia). Dr Tho, indagator activus est et prosperos labores in immunotherapy, pulmone, cancro, capite et collo cancri et cancro nasopharyngeo percucurrit. Ille ordinarius invitatus est orator regionum et internationalium.
Awards

1. Ioannes Paulus Award, PhD Student optimus, UK
2. Medal Hollman Annam, Scotorum Radiological Societate UK
3. Research Fellowship cancer, cancer UK Research (CRUK) / Royal College of radiologists, UK
4. Optimus memoratæ, Annual Scientific fœderis: Pharmacopoeia Collegii Regalis radiologists, UK
5. Research Fellowship cancer, cancer Research Institute for Beatson, UK
6. In Johannem Cicero eu auctor nisl, Australia
7. ASEAN Scholarship, Singapore

• Gamma ferro et SRS Cyberknife
• Intracraniale Stereotactic Radiosurgery (SRS)
• Corpus Stereotactic Rectum (SBRT)
• Corpus Stereotactic Ablativo Rectum (SABR)
• In feruorem: modulatus editur Rectum (IMRT)
• Rectum imago, Lustrationes (IGRT)

lung Cancer. Oct MMXIX; CXXXVI: 2019-136.

Triticum Testing pro non-parva cellula provectus pulmonis cancer in elit, dicitur a College of Consensus Pathologists, summisque in medicina honoribus Academy elit, de Bimembris Dissoluti Societas Malaysian et Oncological Societas Malaysian. Rajadurai P, PI Cheah, SH quam Liam, erunt Annuar Maa, Omar N, N Othman, Marzuki NM, ANGOR YK, Bustamam RSA, Londini LM.

SCALPELLUM. 2019 May 4;393(10183):1819-1830.

Pembrolizumab prius increatos versus chemotherapy in PD-L1-expressing et partim non-parva-cell metastatic vel provectus pulmonis cancer (INCAENTIVUS-XLII): a randomized, aperto-titulus, sobrie, et tempus iudicii III. Mok et al-XLII Indagatores INCENTIVUS.

cancer medicinae. 2015 Aug;4(8):1196-204.

Current dolor cancer administratione exercitia sunt in Asia, a aliquet a medicis et aegris per X terris. ACHEON Regalis Societatis Londini: Kim ad YC, AHN JS, Calimag MM Chao C. Declina paulisper ILTho LMXia ZJ, Daphne L, H, lunam, A. Bhagat

Acta Asian Next tropicum Cancri. 2015;16(5):1901-6.

Parva non-cell carcinoma in patientibus pulmonis pronostico factors metastases et cerebrum, a Malaysian perspective. Tang WH, Alip A, M Saad, Phua VC, Chandran II, tan YH, Tan yy, Kua AR Wahid CA, Londini LM.

BMC Cancer. Mar MMXIV XX: XIV: CCXII

Global claudebant cancer-partitus pectus cancer cura muneris perficiendi ex media in developing patriam reditus. Lim GC seánraí Ethicorum, Cheah SK, Ismail F, Honorius GF, Londini LM, Yip Heth al HPMRS Latin Pectus Cancer Group.

Therapy pro targeted Immunothérapie et Lung Cancer

www.thestar.com.my/news/nation/2017/11/20/targeted-therapy-and-immunotherapy for pulmonis cancer

Pugna Cancer boosting nostra immune ratio

https://www.star2.com/health/2018/09/05/boosting-immune-system-treat-tumours

Profliling quod Humanum Genome

https://www.nst.com.my/lifestyle/heal/2019/09/520171/profiling-human-genome

Sursum autem adversus pectus Cancer

https://www.nst.com.my/lifestyle/heal/2019/10/526132/facing-cancer